Spelman, T. Et Al. 2016. Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer. 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , (London, Canada), 600-602.

Spelman, T., Izquierdo, G., Lugaresi, A., Alroughani, R., Duquette, P., Boz, C., ... Fernandez Bolanos, R.(2016). Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer . 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) (pp.600-602). London, Canada

Spelman, T. Et Al. "Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer," 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 2016

Spelman, T. Et Al. "Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.600-602, 2016

Spelman, T. Et Al. (2016) . "Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer." 32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) , London, Canada, pp.600-602.

@conferencepaper{conferencepaper, author={T. Spelman Et Al. }, title={Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer}, congress name={32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)}, city={London}, country={Canada}, year={2016}, pages={600-602} }